Clinical Trial Update: A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib [Phase 2]

View source ↗

Summary

Phase 2 trial assessing orelabrutinib in CLL/SLL patients with slow response to ibrutinib is ongoing; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: CLL/SLL | Phase 2 | Status: UNKNOWN